select a format

Single User License
USD 3500 INR 224315
Site License
USD 7000 INR 448630
Corporate User License
USD 10500 INR 672945

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Sphingosine 1-Phosphate Receptor 1 S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1-Pipeline Review, H1 2016

Sphingosine 1-Phosphate Receptor 1 S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1-Pipeline Review, H1 2016


  • Products Id :- GMDHC0095TDB
  • |
  • Pages: 71
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)-Pipeline Review, H1 2016', provides in depth analysis on Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted pipeline therapeutics.

The report provides comprehensive information on the Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)

The report reviews Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics and enlists all their major and minor projects

The report assesses Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) Overview 8

Therapeutics Development 9

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)-Products under Development by Stage of Development 9

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)-Products under Development by Therapy Area 10

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)-Products under Development by Indication 11

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)-Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)-Products under Development by Companies 14

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)-Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)-Companies Involved in Therapeutics Development 23

Actelion Ltd 23

Arena Pharmaceuticals, Inc. 24

AstraZeneca Plc 25

Celgene Corporation 26

GlaxoSmithKline Plc 27

Meiji Seika Pharma Co., Ltd. 28

Novartis AG 29

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)-Drug Profiles 30

AKP-11-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

APD-334-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

BMS-986104-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

CBP-307-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Cenerimod-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

CP-9531-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

NIBR-0213-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

ozanimod hydrochloride-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

ponesimod-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

siponimod-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Small Molecule to Agonize S1P1 for Multiple Sclerosis-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Small Molecule to Agonize S1PR1 for Multiple Sclerosis-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Small Molecule to Agonize S1PR1 for Ulcerative Colitis-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Small Molecule to Modulate S1PR1 for Atopic Dermatitis-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)-Dormant Projects 55

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)-Discontinued Products 57

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)-Featured News & Press Releases 58

May 04, 2016: Study Shows Ozanimod as Effective in Treating Ulcerative Colitis 58

Mar 18, 2016: Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial 59

Feb 18, 2016: Oral Ozanimod 72-Week Phase 2 Results From RADIANCE Trial in Relapsing Multiple Sclerosis Presented At ACTRIMS 60

Jan 08, 2016: Suzhou Connect Biopharma Reports Positive Phase 1b Result for Novel S1P1 Modulator CBP-307 for Autoimmune Diseases 61

Dec 14, 2015: Akaal Pharma Announces Superior Safety and Comparable Efficacy of Sphingosine 1-Phosphate Receptor-1 (S1P1) Modulator AKP-11 as Compared to Gilenya (Fingolimod) for the Treatment of Multiple Sclerosis 62

Dec 14, 2015: US Patents Issued to Akaal Pharma on S1P1 Receptor Modulators Useful for the Treatment of Autoimmune and Inflammatory Diseases 63

Oct 26, 2015: Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at UEG Week 63

Oct 19, 2015: Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at ACG Plenary Session 65

Sep 01, 2015: MS Trial Alert: Investigators Recruiting Worldwide for Phase III Clinical Trial of Oral Ponesimod 66

Jul 30, 2015: Suzhou Connect Biopharma Reports Positive Phase 1a Results for CBP-307, a Novel, Orally-active S1P1 Modulator for Autoimmune Diseases 66

Jul 29, 2015: Arena Pharmaceuticals Initiates a Phase 2 Clinical Trial of APD334, its S1P1 Receptor Modulator for Autoimmune Diseases 67

Jul 09, 2015: Suzhou Connect Biopharma Announces Patent Issuance Covering CBP-307-a Clinical-stage Second Generation S1P1 Immune Modulator 67

Jul 01, 2015: Akaal Pharma, Australia extends collaboration with GVK BIO for formulations development services to support Phase 2 Clinical studies for Topical Treatment of Psoriasis 68

Jun 25, 2015: New Data Supporting Gradual Up-Titration Of Ponesimod To Mitigate First-Dose Cardiodynamic Effects To Be Presented At Eacpt 2015 68

Jun 16, 2015: Akaal Pharma Receives Approval to Initiate Phase 2 Clinical Trial for the Topical Treatment of Psoriasis 69

Appendix 70

Methodology 70

Coverage 70

Secondary Research 70

Primary Research 70

Expert Panel Validation 70

Contact Us 70

Disclaimer 71

List of Figures

Number of Products under Development for, H1 2016 9

Number of Products under Development by Therapy Area, H1 2016 10

Number of Products under Development by Top 10 Indication, H1 2016 11

Comparative Analysis by Late Stage Development, H1 2016 12

Comparative Analysis by Early Stage Products, H1 2016 13

Assessment by Monotherapy/Combination Products, H1 2016 17

Number of Products by Mechanism of Actions, H1 2016 18

Number of Products by Stage and Mechanism of Actions, H1 2016 18

Number of Products by Routes of Administration, H1 2016 20

Number of Products by Stage and Routes of Administration, H1 2016 20

Number of Products by Stage and Molecule Type, H1 2016 22

List of Tables

Number of Products under Development for, H1 2016 9

Number of Products under Development by Therapy Area, H1 2016 10

Number of Products under Development by Indication, H1 2016 11

Comparative Analysis by Late Stage Development, H1 2016 12

Comparative Analysis by Early Stage Products, H1 2016 13

Number of Products under Development by Companies, H1 2016 14

Products under Development by Companies, H1 2016 15

Products under Development by Companies, H1 2016 (Contd..1) 16

Assessment by Monotherapy/Combination Products, H1 2016 17

Number of Products by Stage and Mechanism of Action, H1 2016 19

Number of Products by Stage and Route of Administration, H1 2016 21

Number of Products by Stage and Molecule Type, H1 2016 22

Pipeline by Actelion Ltd, H1 2016 23

Pipeline by Arena Pharmaceuticals, Inc., H1 2016 24

Pipeline by AstraZeneca Plc, H1 2016 25

Pipeline by Celgene Corporation, H1 2016 26

Pipeline by GlaxoSmithKline Plc, H1 2016 27

Pipeline by Meiji Seika Pharma Co., Ltd., H1 2016 28

Pipeline by Novartis AG, H1 2016 29

Dormant Projects, H1 2016 55

Dormant Projects (Contd..1), H1 2016 56

Discontinued Products, H1 2016 57

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Actelion Ltd

Arena Pharmaceuticals, Inc.

AstraZeneca Plc

Celgene Corporation

GlaxoSmithKline Plc

Meiji Seika Pharma Co., Ltd.

Novartis AG

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) Therapeutic Products under Development, Key Players in Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) Therapeutics, Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) Pipeline Overview, Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) Pipeline, Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com